Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Allergy Clin Immunol. 2017 Apr 13;140(4):1043–1053.e8. doi: 10.1016/j.jaci.2017.03.028

Fig 5.

Fig 5

Percent of MOIT doses that led to moderate-severe (Mod/Severe) symptoms, Gl symptoms, or any symptom excluding oropharyngeal (Symptoms excl. oral) over the course of MOIT in subjects whose baseline basophil %CD63 expression at milk stimulant concentration 10μg/mL was less than or greater than 40% (%CD63 Milk 10>40 or <40, respectively). P-values are indicated in the graphs.